As­traZeneca bags a ‘break­through’ for bruised check­point drug Imfinzi; In­otek CSO takes the helm at Flex

→ Just days af­ter a dam­ag­ing fail­ure for du­val­um­ab (Imfinzi) in a com­bi­na­tion ap­proach to lung can­cer, the FDA has des­ig­nat­ed As­traZeneca’s check­point in­hibitor as a “break­through” prod­uct de­serv­ing spe­cial treat­ment at the agency. Specif­i­cal­ly, the BTD is for lo­cal­ly-ad­vanced, un­re­sectable non-small cell lung can­cer (NSCLC) whose dis­ease has not pro­gressed fol­low­ing plat­inum-based chemora­di­a­tion ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.